This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Talking IUS with young women

Recorded webinars

Talking IUS with young women​

Recorded Tuesday, 27th February, 2024 ​

This free to attend webinar is part of the “Women’s Health Matters” medical educational programme which aims to inspire, update and support healthcare professionals with an interest in women’s health.

 

Session 1
|
Session 2

Talking IUS with Young Women

The individual speaker presentations from

Bayer's Talking IUS with Young Women
webinar can be viewed below.​

Session 1:

Dr Amy Purcell

Dr Amy Purcell

GP with a specialist interest in women’s health, Old Windmill Medical Centre, Limerick

In her presentation Dr Purcell provides an overview of the three intrauterine systems (Kyleena, Mirena and Jaydess), how the free contraception scheme has impacted the types of contraception being prescribed and the benefits of prescribing the IUS to younger patients.

Duration time
| 26 minutes

 

Kyleena® Prescribing Information, Mirena® Prescribing Information, Jaydess®▼ Prescribing Information

Dr Louise Fitzgerald

Dr Louise Fitzgerald

GP with a specialist interest in women’s health, Grafton Medical, Dublin 

In her presentation Dr Fitzgerald share insights into handling objections and concerns among younger patients in choosing an IUS and how she prepares younger patient for an IUS insertion including pain management discussion.

Duration time
| 19 minutes

Session 2:

 

Kyleena® Prescribing Information, Mirena® Prescribing Information, Jaydess®▼ Prescribing Information

​These meetings are part of the Women’s Health Matters Educational Programme that are organised and fully funded by Bayer.

 

PP-PF-WHC-IE-0921-1   |   February 2026